# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Examiner:

BRANNOCK, Michael T.

XIA, et al.

Art Unit:

1646

Application No.: 09/886,041

Filed: June 22, 2001

Title: A NOVEL G PROTEIN-COUPLED

**RECEPTOR, GAVE3** 

eby certify that this correspondence is being ited with the United States Postal Service as First Mail in an envelope addressed to Commissioner attents, P.O. Box 1450, Alexandria, VA 22313-

### TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED

Mail Stop Patent Application Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. 18-1982 in the amount of \$180.00. Two duplicate copies of this sheet are enclosed. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

Respectfully submitted,

Joel B. German, Reg. No. 48,676

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-3444 Telefax (908) 231-2626

Aventis Docket No. USAV2001/0055 US NP

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of XIA, et al.

Application No.: 09/886,041

Filed: June 22, 2001

Title: A NOVEL G PROTEIN-COUPLED RECEPTOR, GAVE3

Examiner:

BRANNOCK, Michael T.

Art Unit:

1646

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for fatents, P.O. Box 1450, Alexandria, VA 22313-14501 on

20 January 2004

Storiature

#### INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop Patent Application Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

01/27/2004 MAHMED1 00000084 181982 09886041

01 FC:1806

180.00 DA

-1-

- (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R.

  1.97(b), but is believed to be filed before the mailing date of a final action under §1.113

  or a notice of allowance under §1.311, whichever occurs first.
  - (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
  - [2] The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
  - (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,

Joel B. German, Reg. No. 48,676 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3444
Telefax (908) 231-2626

Aventis Docket No. USAV2001/0055 US NP

•		
e type a plus	sign (+) inside this b	, ox →

type a plus sign (+) inside this box 
PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

2 Sheet of

Complete if Known					
Application Number	09/886,041				
Filing Date	06-22-2001				
First Named Inventor	XIA, et al.				
Group Art Unit	1646				
Examiner Name	BRANNOCK, Michael T.				
Attorney Docket Number	USAV2001/0055 - US - NP				

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	U.S. Paten Number	t Documer Kind Co (if know	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	T						
•			İ				
	$\neg \neg$	-		·			
						-	
			<del>-  -</del>				
						<del></del>	
			_	<u></u>			
	$\neg \neg$						

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document  Office <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)		Kind Code <sup>5</sup> Applicant of Cited Document Cited Do		Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6	
		wo	01/36471			Arena Pharmaceuticals, Inc.	05-25-2001		
									$oldsymbol{oldsymbol{\sqcup}}$
									$\perp$
		<u> </u>							$oldsymbol{oldsymbol{\sqcup}}$
		<b>.</b>							igspace
									+-+
									$\vdash$
									$oldsymbol{ol}}}}}}}}}}}}}}}}}}$

Examiner	 Date	
Signature	Considered	
Cignature	 1	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.